A Single Centre, Prospective, Randomized, Open Labelled Clinical Study to Evaluate the Effectiveness of Siddha Poly Herbal Formulation, Viprotm, Towards the Management of Uncomplicated Respiratory Infection

The objective was to evaluate the efficacy of ViproTM, a polyherbal formulation in the management of uncomplicated respiratory infection towards reducing the severity of clinical symptoms, reducing the worsening of clinical symptoms&complications and to determine its safety by detectingadverse events. The study was started after obtaining approval from Institutional Human Ethics Committee. It was a prospective, randomized controlled study done in 60 patients. Patients having uncomplicated respiratory infections, at least for less than 5 days, with clinical symptoms and signs of fever, myalgia, rhinitis, sore throat, throat pain, cough, expectoration and head ache were enrolled and randomly allocated to one of the three groups, A, B and C. Group A received standard treatment, group B ViproTM and group C ViproTM along with the standard treatment. All the patients were followed up for a period of 7 days from starting treatment. Telephonic follow up was done daily for 7 days and physical follow up on day 0, day 4 and day 7. During physical follow up, vitals & body temperature were recorded, general and systemic examination done, adverse events were noted and improvement in constitutional symptoms was assessed. Complete blood count (CBC) and nasal / throat swab for culture were done at the baseline and at the end of study. Vipro TM has demonstrated efficacy in alleviating the clinical symptoms similar to standard treatment. With regard to safety, ViproTM is associated with a few adverse events and all of them are minor in nature and subsided within 24 hours.